CA2122519C - Traitement du cancer et prevention des metastases - Google Patents

Traitement du cancer et prevention des metastases Download PDF

Info

Publication number
CA2122519C
CA2122519C CA002122519A CA2122519A CA2122519C CA 2122519 C CA2122519 C CA 2122519C CA 002122519 A CA002122519 A CA 002122519A CA 2122519 A CA2122519 A CA 2122519A CA 2122519 C CA2122519 C CA 2122519C
Authority
CA
Canada
Prior art keywords
cancer
hyaluronic acid
drug
combinations
daltons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002122519A
Other languages
English (en)
Other versions
CA2122519A1 (fr
Inventor
Rudolf Edgar Dr. Falk
Samuel Simon Asculai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchemia Oncology Pty Ltd
Original Assignee
Hyal Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002122519A priority Critical patent/CA2122519C/fr
Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp
Priority to AU24023/95A priority patent/AU696373B2/en
Priority to SK1379-96A priority patent/SK137996A3/sk
Priority to CN95193689A priority patent/CN1151118A/zh
Priority to JP7528564A priority patent/JPH09512797A/ja
Priority to RU96122884/14A priority patent/RU2162327C2/ru
Priority to HU9602965A priority patent/HUT75868A/hu
Priority to CZ963089A priority patent/CZ308996A3/cs
Priority to KR1019960706101A priority patent/KR970702728A/ko
Priority to PCT/CA1995/000259 priority patent/WO1995030423A2/fr
Priority to EP95917846A priority patent/EP0760667A1/fr
Publication of CA2122519A1 publication Critical patent/CA2122519A1/fr
Application granted granted Critical
Publication of CA2122519C publication Critical patent/CA2122519C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002122519A 1991-07-03 1994-04-29 Traitement du cancer et prevention des metastases Expired - Lifetime CA2122519C (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002122519A CA2122519C (fr) 1994-04-29 1994-04-29 Traitement du cancer et prevention des metastases
KR1019960706101A KR970702728A (ko) 1994-04-29 1995-04-28 암치료와 전이예방(Cancer Treatment and Metastasis Prevention)
CN95193689A CN1151118A (zh) 1994-04-29 1995-04-28 癌症的治疗与预防转移
JP7528564A JPH09512797A (ja) 1994-04-29 1995-04-28 癌の治療および転移の予防
RU96122884/14A RU2162327C2 (ru) 1994-04-29 1995-04-28 Лечение рака и профилактика метастазирования
HU9602965A HUT75868A (en) 1994-04-29 1995-04-28 Process for preparing pharmaceuticals with anti cancer activity
AU24023/95A AU696373B2 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
SK1379-96A SK137996A3 (en) 1994-04-29 1995-04-28 Cancer treatment and metastasis prevention
PCT/CA1995/000259 WO1995030423A2 (fr) 1991-07-03 1995-04-28 Traitement du cancer et prevention des metastases
EP95917846A EP0760667A1 (fr) 1994-04-29 1995-04-28 Traitement du cancer et prevention des metastases
CZ963089A CZ308996A3 (cs) 1994-04-29 1995-04-28 Kombinace dávkových množství farmaceutického prostředku pro léčení rakoviny u člověka, použití dávkových množství léčiva proti rakovině a kyseliny hyaluronové a farmaceutické prostředky

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002122519A CA2122519C (fr) 1994-04-29 1994-04-29 Traitement du cancer et prevention des metastases

Publications (2)

Publication Number Publication Date
CA2122519A1 CA2122519A1 (fr) 1995-10-30
CA2122519C true CA2122519C (fr) 2001-02-20

Family

ID=4153495

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002122519A Expired - Lifetime CA2122519C (fr) 1991-07-03 1994-04-29 Traitement du cancer et prevention des metastases

Country Status (11)

Country Link
EP (1) EP0760667A1 (fr)
JP (1) JPH09512797A (fr)
KR (1) KR970702728A (fr)
CN (1) CN1151118A (fr)
AU (1) AU696373B2 (fr)
CA (1) CA2122519C (fr)
CZ (1) CZ308996A3 (fr)
HU (1) HUT75868A (fr)
RU (1) RU2162327C2 (fr)
SK (1) SK137996A3 (fr)
WO (1) WO1995030423A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512604B2 (en) 2006-09-22 2019-12-24 Yasuhiro Ogawa Radiation sensitizer or anti-cancer chemotherapy sensitizer

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
CA2175282A1 (fr) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
CA2208924A1 (fr) * 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Utilisation reduite de paclitaxel grace a l'hyaluronan
GB9716219D0 (en) * 1997-07-31 1997-10-08 Geistlich Soehne Ag Prevention of metastases
US7151099B2 (en) 1998-07-31 2006-12-19 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Use of taurolidine and/or taurultam for treatment of abdominal cancer and/or for the prevention of metastases
US8304390B2 (en) 1997-07-31 2012-11-06 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Method of treatment for preventing or reducing tumor growth in the liver of patient
IL134593A0 (en) * 1997-08-29 2001-04-30 Biogen Inc A cell system for in-vivo expression of an interferon beta protein, pharmaceutical compositions containing the same and methods for the preparation thereof
JP4790911B2 (ja) * 1999-01-13 2011-10-12 アルケミア オンコロジー ピーティワイ リミテッド 薬物の効力を増強するための組成物および方法
WO2000048597A1 (fr) 1999-02-18 2000-08-24 Novartis Ag Utilisation systemique d'antagonistes du recepteur 5-ht3 contre des processus inflammatoires rhumatismaux
US8030301B2 (en) 1999-06-04 2011-10-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
US7892530B2 (en) 1999-06-04 2011-02-22 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of tumor metastases and cancer
US7345039B2 (en) 1999-06-04 2008-03-18 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
EP1250152B1 (fr) 1999-12-28 2013-05-15 Bioniche Urology IP Inc. Composition synergique contenant de l'acide hyaluronique dans le traitement du cancer
US6641571B2 (en) 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
CA2513143A1 (fr) * 2002-07-01 2004-01-08 Tufts University Methodes et compositions permettant d'inhiber la resistance pleiotrope au moyen d'oligomeres d'hyaluronane
US20060003027A1 (en) * 2004-06-30 2006-01-05 Zhou James H Composition and method for reducing side effects of indole-3-carbinol and derivatives
WO2007012133A1 (fr) * 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Protocoles thérapeutiques utilisant hyaluronan
EP1922077A4 (fr) 2005-09-07 2013-03-06 Alchemia Oncology Pty Ltd Compositions thérapeutiques comprenant de l hyaluronane et des anticorps therapeutiques, et procédes thérapeutiques
KR100856114B1 (ko) * 2008-04-18 2008-09-02 강지민 리모컨을 이용한 텔레비전 음향과 데이터 송수신방법
WO2010056378A2 (fr) * 2008-11-14 2010-05-20 Histogen, Inc. Compositions de matrice extracellulaire pour le traitement du cancer
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
RU2586043C1 (ru) * 2014-11-12 2016-06-10 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" Способ профилактики и лечения осложнений при лучевой терапии рака кожи
RU2723883C2 (ru) * 2018-07-17 2020-06-18 Николай Васильевич Цугленок Способ инициации гибели опухолевых клеток аскорбиновой и гидрозидом 3-аминофталевой кислотами и ВЧ- и СВЧ-энергией волнового излучения

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
CA2061703C (fr) * 1992-02-20 2002-07-02 Rudolf E. Falk Compositions renfermant de l'acide hyaluronique
CA2061566C (fr) * 1992-02-20 2002-07-09 Rudolf E. Falk Traitement des maladies par l'acide hyaluronique et des ains
CA2097892A1 (fr) * 1993-06-07 1994-12-07 Rudolf Edgar Falk Prevention du cancer et lutte contre le cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512604B2 (en) 2006-09-22 2019-12-24 Yasuhiro Ogawa Radiation sensitizer or anti-cancer chemotherapy sensitizer
US10758477B2 (en) 2006-09-22 2020-09-01 Yasuhiro Ogawa Radiation sensitizer or anti-cancer chemotherapy sensitizer

Also Published As

Publication number Publication date
CN1151118A (zh) 1997-06-04
CA2122519A1 (fr) 1995-10-30
HU9602965D0 (en) 1997-01-28
CZ308996A3 (cs) 1998-01-14
RU2162327C2 (ru) 2001-01-27
KR970702728A (ko) 1997-06-10
WO1995030423A2 (fr) 1995-11-16
WO1995030423A3 (fr) 1995-12-21
HUT75868A (en) 1997-05-28
AU2402395A (en) 1995-11-29
SK137996A3 (en) 1998-08-05
JPH09512797A (ja) 1997-12-22
AU696373B2 (en) 1998-09-10
EP0760667A1 (fr) 1997-03-12

Similar Documents

Publication Publication Date Title
CA2122519C (fr) Traitement du cancer et prevention des metastases
EP0656213B1 (fr) Utilisation combinee de l'acide hyaluronique et d'agents therapeutiques pour ameliorer l'effet therapeutique
US5614506A (en) Use of hyaluronic acid and forms to prevent arterial restenosis
HU211823A9 (en) Formulations containing hyaluronic acid
HU225963B1 (en) Process for producing pharmaceutical compositions for the treatment of basal cell carcinoma and actinic keratoses
AU694113B2 (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
US5674857A (en) Use of hyaluronic acid to repair ischemia reperfusion damage
WO2005099749A2 (fr) Methodes pour controler une angiogenese et une proliferation cellulaire
CA2175282A1 (fr) Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
US5847002A (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
AP619A (en) Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
US5817642A (en) Clearing of atherosclerosis
JP4210330B2 (ja) ヒアルロン酸レセプター結合剤、およびその使用方法
US5817644A (en) Targeting of dosages of medicine and therapeutic agents
EP0758246A1 (fr) Composition pharmaceutique comprenant de l'acide hyaluronique et destinee a eliminer l'arteriosclerose
CA2167044C (fr) Administration par voie orale de quantites efficaces de certaines formes d'acide hyaluronique
CA2164260C (fr) Methode de ciblage pour medicaments et agents therapeutiques
CA2121454A1 (fr) Inhibition, elimination et regression de l'angiogenese
CZ288292B6 (en) Compound therapeutic preparations intended for treatment of diseases or states of tissues comprising insufficiently perfused tissues and pathological tissues of human being

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140429